275 related articles for article (PubMed ID: 31856437)
41. Neuropathy and paraproteins: review of a complex association.
Rajabally YA
Eur J Neurol; 2011 Nov; 18(11):1291-8. PubMed ID: 21418441
[TBL] [Abstract][Full Text] [Related]
42. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies.
Latov N
Ann Neurol; 1995 May; 37 Suppl 1():S32-42. PubMed ID: 8968215
[TBL] [Abstract][Full Text] [Related]
43. Waldenström's macroglobulinemia and peripheral neuropathy: a clinical and immunologic study of 25 patients.
Dellagi K; Dupouey P; Brouet JC; Billecocq A; Gomez D; Clauvel JP; Seligmann M
Blood; 1983 Aug; 62(2):280-5. PubMed ID: 6307428
[TBL] [Abstract][Full Text] [Related]
44. [Detection of antibodies binding to myelin in 75 neuropathies associated with IgM gammopathy].
Campant RM; Caudie C; Kopp N; Lombard C; Later R
Ann Biol Clin (Paris); 1999; 57(1):69-75. PubMed ID: 9920969
[TBL] [Abstract][Full Text] [Related]
45. Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy.
Gazzola S; Delmont E; Franques J; Boucraut J; Salort-Campana E; Verschueren A; Sagui E; Hubert AM; Pouget J; Attarian S
J Neurol Sci; 2017 Jun; 377():144-148. PubMed ID: 28477685
[TBL] [Abstract][Full Text] [Related]
46. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy.
Kuijf ML; Eurelings M; Tio-Gillen AP; van Doorn PA; van den Berg LH; Hooijkaas H; Stork J; Notermans NC; Jacobs BC
Neurology; 2009 Sep; 73(9):688-95. PubMed ID: 19720975
[TBL] [Abstract][Full Text] [Related]
47. Monoclonal gammopathy and neuropathy.
Lozeron P; Adams D
Curr Opin Neurol; 2007 Oct; 20(5):536-41. PubMed ID: 17885441
[TBL] [Abstract][Full Text] [Related]
48. Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy.
Briani C; Visentin A; Salvalaggio A; Cacciavillani M; Trentin L
Eur J Neurol; 2019 Feb; 26(2):371-375. PubMed ID: 30315672
[TBL] [Abstract][Full Text] [Related]
49. Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy.
Gruson B; Ghomari K; Beaumont M; Garidi R; Just A; Merle P; Merlusca L; Marolleau JP; Royer B
J Peripher Nerv Syst; 2011 Sep; 16(3):180-5. PubMed ID: 22003932
[TBL] [Abstract][Full Text] [Related]
50. Uncommon Presentation of IgM Monoclonal Gammopathy of Undetermined Significance (MGUS) and Anti-Myelin-Associated Glycoprotein (MAG)-Associated Demyelinating Peripheral Neuropathy as Respiratory Failure: A Case Report.
Tanariyakul M; Takaoka K; Takahashi T; Estaris J; Sumida K
Cureus; 2024 Jun; 16(6):e62865. PubMed ID: 38912071
[TBL] [Abstract][Full Text] [Related]
51. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study.
Iancu Ferfoglia R; Guimarães-Costa R; Viala K; Musset L; Neil J; Marin B; Léger JM
J Peripher Nerv Syst; 2016 Mar; 21(1):10-4. PubMed ID: 26748872
[TBL] [Abstract][Full Text] [Related]
52. Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen-specific glycopolymer.
Aliu B; Demeestere D; Seydoux E; Boucraut J; Delmont E; Brodovitch A; Oberholzer T; Attarian S; Théaudin M; Tsouni P; Kuntzer T; Derfuss T; Steck AJ; Ernst B; Herrendorff R; Hänggi P
J Neurochem; 2020 Sep; 154(5):486-501. PubMed ID: 32270492
[TBL] [Abstract][Full Text] [Related]
53. Waldenstrom-associated anti-MAG paraprotein polyneuropathy with neurogenic tremor.
Canepa C
BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30936346
[TBL] [Abstract][Full Text] [Related]
54. [Anti-MAG paraproteinemic demyelinating polyneuropathy: a clinical, biological, electrophysiological and anatomopathological descriptive study of a 13-patients' cohort].
Launay M; Delmont E; Benaim C; Sacconi S; Butori C; Desnuelle C
Rev Neurol (Paris); 2009 Dec; 165(12):1071-9. PubMed ID: 19487003
[TBL] [Abstract][Full Text] [Related]
55. Polyneuropathy associated with IgM vs IgG monoclonal gammopathy: comparison between clinical and electrophysiological findings.
Vrethem M; Reiser N; Lauermann C; Svanborg E
Acta Neurol Scand; 2010 Jul; 122(1):52-7. PubMed ID: 20003083
[TBL] [Abstract][Full Text] [Related]
56. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies.
Nobile-Orazio E; Barbieri S; Baldini L; Marmiroli P; Carpo M; Premoselli S; Manfredini E; Scarlato G
Acta Neurol Scand; 1992 Jun; 85(6):383-90. PubMed ID: 1379409
[TBL] [Abstract][Full Text] [Related]
57. Delayed appearance of anti-myelin-associated glycoprotein antibodies in a patient with chronic demyelinating polyneuropathy.
Valldeoriola F; Graus F; Steck AJ; Muñoz E; de la Fuente M; Gallart T; Ribalta T; Bombí JA; Tolosa E
Ann Neurol; 1993 Sep; 34(3):394-6. PubMed ID: 7689821
[TBL] [Abstract][Full Text] [Related]
58. [Beneficial effects of rituximab in a case of anti-myelin antibody-associated neuropathy].
Shimoyama T; Yaguchi H; Sengoku R; Matsuno H; Mitsumura H; Kono Y; Mochio S
Rinsho Shinkeigaku; 2011 May; 51(5):345-9. PubMed ID: 21706832
[TBL] [Abstract][Full Text] [Related]
59. Paraproteinemic neuropathies.
Vital A
Brain Pathol; 2001 Oct; 11(4):399-407. PubMed ID: 11556684
[TBL] [Abstract][Full Text] [Related]
60. [Neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein (MAG) antibody].
Kawagashira Y; Koike H; Sobue G
Nihon Rinsho; 2015 Sep; 73 Suppl 7():440-5. PubMed ID: 26480739
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
